SEC Comment Letter for Propanc Biopharma, Inc. (PPCB) (CIK 0001517681) (PPCB) — Aug 19, 2011
Propanc Biopharma, Inc. (PPCB) (CIK 0001517681)
Date: Aug. 19, 2011 · CIK: 0001517681 · Accession: 0000000000-11-050299
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-175092
Letter
August 19, 2011 Via E-mail Mr. James Nathanielsz, Chief Executive Officer Propanc Health Group Corporation 576 Swan Street Richmond, VIC, 3121, Australia Re: Propanc Health Group Corporation Registration Statement on Form S-1 Amendment No. 1 filed August 18, 2011 File No. 333-175092
Dear Mr. Nathanielsz: Our preliminary review of the above referenc ed amendment to your registration statement indicates that it fails in various material respects to comply with the requirements of the Securities Act of 1933, the rules an d regulations under that Act, and th e requirements of the form. Namely, the financial statements included in the filing are not current as required by Article 8-08 of Regulation S-X. In addition, your next amendment should include an updated accountant’s consent. We will not perform a detailed ex amination of the regi stration statement an d we will not issue comments because to do so would delay the review of othe r disclosure documents that do not appear to contain comp arable deficiencies.
If you were to request acceleratio n of the effective date of the registration statement in its present form, we would likely reco mmend that the Commissi on deny your request. We suggest that you consider filing a substa ntive amendment to correct the deficiencies.
Sincerely,
/s/ Daniel Greenspan for Jeffrey Riedler
Assistant Director
cc: Peter J. Gennuso, Esquire
Show Raw Text
August 19, 2011 Via E-mail Mr. James Nathanielsz, Chief Executive Officer Propanc Health Group Corporation 576 Swan Street Richmond, VIC, 3121, Australia Re: Propanc Health Group Corporation Registration Statement on Form S-1 Amendment No. 1 filed August 18, 2011 File No. 333-175092 Dear Mr. Nathanielsz: Our preliminary review of the above referenc ed amendment to your registration statement indicates that it fails in various material respects to comply with the requirements of the Securities Act of 1933, the rules an d regulations under that Act, and th e requirements of the form. Namely, the financial statements included in the filing are not current as required by Article 8-08 of Regulation S-X. In addition, your next amendment should include an updated accountant’s consent. We will not perform a detailed ex amination of the regi stration statement an d we will not issue comments because to do so would delay the review of othe r disclosure documents that do not appear to contain comp arable deficiencies. If you were to request acceleratio n of the effective date of the registration statement in its present form, we would likely reco mmend that the Commissi on deny your request. We suggest that you consider filing a substa ntive amendment to correct the deficiencies. Sincerely, /s/ Daniel Greenspan for Jeffrey Riedler Assistant Director cc: Peter J. Gennuso, Esquire